CURIGIN

Curigin is a company focused on the development of new drugs with a sincere passion for research and development. After developing an adenoviral vector capable of delivering bispecific RNAi in 2018, more than 5 types of vectors and 15 pipelines have been developed based on our original new drug development platform technology and three independent gene discovery libraries. Further, globally competitive technologies such as a new virus platform, two viruses that can be administered intravenously, and development of an RNAi-based library have been added to our arsenal of therapeutic tools. Despite the difficulties associated with new drug development, we believe that developing innovative therapeutics is our mission and we are steadily working towards that goal. We will continue to race on the path of new drug development through ceaseless research and positive outcomes... Core Values Curigin cultivates a culture centered on open communication between all members. While new drug..